Cardiovascular Diseases in CKD

Similar documents
HTA ET DIALYSE DR ALAIN GUERIN

Coronary artery disease (CAD) risk factors

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

Blood Pressure Monitoring in Chronic Kidney Disease

Optimal blood pressure targets in chronic kidney disease

Arterial Pressure in CKD5 - ESRD Population Gérard M. London

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Early Detection of Damaged Organ

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

THE IMPACT OF CCB AND RAS INHIBITOR COMBINATION THERAPY TO PREVENT CKD INCIDENCE IN HYPERTENSION AND ADVANCED ATHEROSCLEROSIS

ARTERIAL STIFFNESS ASSESSMENT COMMENTS:

Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease

KDIGO LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient

Systolic Blood Pressure Intervention Trial (SPRINT)

Metabolic Syndrome and Chronic Kidney Disease

Nephrology Unit- CHU Liège- Ulg- Belgium

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

Chapter 4: Cardiovascular Disease in Patients With CKD

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Antihypertensive Trial Design ALLHAT

CKD and risk management : NICE guideline

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Correlation between Left Atrial Diameter and Renal Outcomes in Chronic Kidney Disease Patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

surtout qui n est PAS à risque?

Cardiovascular Risk Reduction in Kidney Transplant Recipients

Echocardiography analysis in renal transplant recipients

The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

CVD risk assessment using risk scores in primary and secondary prevention

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

Interventions to reduce progression of CKD what is the evidence? John Feehally

CARDIO-RENAL SYNDROME

Diagnosis is it really Heart Failure?

T. Suithichaiyakul Cardiomed Chula

Insulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults

Update on Current Trends in Hypertension Management

hypertension Head of prevention and control of CVD disease office Ministry of heath

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

SUPPLEMENTAL MATERIAL

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis

Individual Study Table Referring to Part of Dossier: Volume: Page:

Predicting and changing the future for people with CKD

Estrogens vs Testosterone for cardiovascular health and longevity

Importance of Ambulatory Blood Pressure Monitoring in Adolescents

Causes of death in Diabetes

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

When should you treat blood pressure in the young?

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

HYPERTENSION AND HEART FAILURE

Theoretical and practical questions in the evaluation of arterial function Miklós Illyés MD. Ph.D.

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

The New Hypertension Guidelines

Relationship between Arterial Stiffness and the Risk of Coronary Artery Disease in Subjects with and without Metabolic Syndrome

Chapter 4: Cardiovascular Disease in Patients with CKD

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Approach to patient with hypertension. Dr. Amitesh Aggarwal

Hypertension Management in Diabetic Patients

Morbidity & Mortality from Chronic Kidney Disease

HFpEF, Mito or Realidad?

egfr > 50 (n = 13,916)

EARLY DETECTION OF DIABETES COMPLICATIONS AUTONOMIC NERVOUS SYSTEM AND VASCULAR FUNCTION ASSESSMENTS

Targeting vascular damage (stiffness, calcifications) in CKD: beyond blood pressure

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Outcomes of dialysis in the elderly. DNT March 2011 Dr Céline Foote

Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

Improved survival of type 2 diabetic patients on renal replacement therapy in Finland

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

Background. Metabolic syndrome T2DM CARDIOVASCULAR DISEASE. Major Unmet Clinical Need. Novel Risk Factors. Classical Risk Factors LDL-C.

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

Egyptian Hypertension Guidelines

Prevention of Cardiovascular Disease

LD TECHNOLOGY PRODUCT CATALOG

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Blood Pressure Treatment Goals

The Author(s) This article is published with open access by ASEAN Federation of Cardiology

Departments of Cardiology and Vascular Surgery Michaelidion Cardiac Center University of Ioannina, Greece

Transcription:

1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1

2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9

3 High CV Mortality in ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9

CKD Increased Risks of Death, CV Events & Hospitalization 4 Go AS et al, NEJM 2004;351:1296-305

5 Cardiorenal Syndrome Ronco C, Contrib Nephrol. 2010;164:33-8

Traditional and Nontraditional Risk Factors for CVD in CKD 6 Menon V et al, AJKD 2005;45:223-32

Our Findings of Some Nontraditional CV Risk Factors in CKD Patients 7 Cardiac structural changes Heeart Echo Parameters, Surface ECG P wave, bpep/bet (brachial pre-ejection period/ejection time) Framingham risk score Arterial stiffness bapwv (Pulse wave velocity) Four limb BP Volume status Metabolic changes: Hyperuricemia, Anemia, BMI

Increased LVMI & Decreased LVEF Correspond with CKD Stages in DM 8 LVMI LVEF LVH LVEF<55% A cross-sectional study enrolled 285 DM with CKD stages 3-5 Chen & Chen, Exp Diabetes Res 2012;2012:789325

ECG Parameters are Associated with Increased CV Events in CKD 9 LAD<4.7cm LVEF>55% LAD>4.7cm LVEF<55% HR 2.141, P=0.016 HR 2.007, P=0.028 N=505, Stage 3-5 Chen & Chen, NDT 2012;27:1064-70

10 Inappropriate LVM is Associated with Increased CV Events in CKD Appropriate LVM Log-rank P = 0.036 Inappropriate LVM N=485, Stage 3-5 Chen & Chen, Hypertens Res. 2012;35:832-8

11 Concentric LVH is Associated with Progression to Dialysis in CKD Non-LVH Concentric LVH Eccentric LVH HR 2.03, P=0.049 A longitudinal study enrolled 415 stage 3-5 Pts Chen & Chen, CJASN 2011;6:2750-8

High UA & LVMI are Associated with Rapid Renal Progression & Dialysis 12 N=540, Stage 3-5, Follow 33.4m, Rapid progressor: egfr >-3/y Chen & Chen, Am J Hypertens 2013;26:243-9

Anemia & LVH are Associated with Renal Function Decline & CV Events 13 High Hb, LVH(-) Low Hb, LVH(-) High Hb, LVH(+) Low Hb, LVH(+) N=415, Stage 3-5 Chang & Chen, Am J Med Sci 2014; 347:183-9

14 High BMI better? Low BMI better?

15 Combination of Lower BMI & Higher LVMI is Associated with CV Events in CKD Parameters Unadjusted Multivariate adjusted (1) Multivariate adjusted (2) hazard ratio (95% CI) p hazard ratio (95% CI) p hazard ratio (95% CI) p Higher BMI and lower LVMI Lower BMI and LVMI Higher BMI and LVMI Lower BMI and higher LVMI 1 1 1 1.060 (0.490-2.293) 0.882 1.465 (0.646-3.322) 0.361 2.006 (0.768-5.240) 0.155 2.146 (1.094-4.206) 0.026 1.965 (0.973-3.966) 0.060 2.058 (0.900-4.710) 0.087 3.178 (1.645-6.140) 0.001 3.511 (1.744-7.072) < 0.001 3.553 (1.494-8.450) 0.004 Multivariate model (1): adjusted for age, diabetes mellitus, hypertension, coronary artery disease, atrial fibrillation, systolic blood pressure, and pulse pressure. Multivariate model (2): model (1) + albumin, fasting glucose, log triglyceride, total cholesterol, hemoglobin, egfr, proteinuria, and ACEI and/or ARB use. N=523, Stage 3-5 Chen & Chen, Am J Med Sci. 2016 351:91-6

16 Combination of High LAD & Low Albumin is Associated with Renal Function Decline and Dialysis L LAD L LAD H LAD H LAD H Alb L balb H Alb L Alb N=395, Stage 3-5 Chen & Chen, Int J Med Sci 2013;10:575-84

17 12-Lead ECG P Wave The 12-lead ECG (P wave morphology, P wave dispersion, P wave duration) is a simple and cheap noninvasive clinical tool to access left atrial enlargement, left ventricular hypertrophy, and left ventricular diastolic dysfunction. Arch Intern Med 1989; 149: 1161-1165 Furthermore, P wave parameters were independently associated with increased risks for atrial fibrillation and recurrent transient ischemic attacks. South Med J 2008; 101: 246-251 Am J Cardiol 107: 917-921 e911

18 High ECG P Wave Dispersion & Maximum P Wave Duration are Associated with Progression to Dialysis & Death Higher P Dispersion Higher Max P Duration N=439, Stage 3-5 Chen & Chen, PLoS One. 2014;9:e101962

19 Framingham Risk Score The Framingham Risk Score is a gender-specific algorithm used to estimate the 10-year cardiovascular risk. It contains age, sex, total and HDL cholesterol, BP, smoking.

Framingham Risk Score (FRS) in HD: Intermediate Risk Pts have Higher Mortality Rate 20 N=201, Follow 4.4±1.5y Huang & Chen, Nephrology 2013;18:510-5

FRS in CKD: ECG Parameters Increased FRS Predictive Power for CV Events 21 Parameters Cardiovascular events FRS 0.589 AUCs Change in c- statistic FRS + albumin 0.793 0.204 FRS + hemoglobin 0.768 0.179 FRS + egfr 0.756 0.167 FRS + proteinuria 0.678 0.089 FRS + LA diameter > 4.7 cm 0.725 0.136 FRS + LVH 0.700 0.111 FRS + LVEF < 50% 0.648 0.059 Chen & Chen, PLoS One 2013;8:e60008

Colin VP System

VP1000 - ABI, bapwv, bpep/bet 1.ABI/API (Ankle Brachial Pressure Index) Lower extremity artery stenosis Arteriosclerosis Arterial stiffness 2. PWV (Pulse Wave Velocity) Artery stiffness 3. bpep/bet(brachial pre-ejection period/brachilal ejection time) Systolic time interval (STI)

24 Good Correlation Between Brachial and ECG Systolic Time Interval (STI) R=0.708, P<0.001 PEP/ET(Pre-ejection period/ejection time): STI N=849, General Chen & Su, PLoS One 2013;8:e55840

Higher bpep/bet is Associated with Higher LVMI and Lower LVEF in CKD 25 r = 0.360, P < 0.001 r = -0.445, P < 0.001 bpep/bet(brachial pre-ejection period/brachilal ejection time): STI N=243, Stage 3-5 Chen & Su, NDT 2011;26:1895-902

26 bpep/bet is Associated with Increassed CV Events in CKD N=242, Stage 3-5 Chen & Chen, Circ J 2010 ;24;74:2206-10

27 Both ABI<0.9 & 1.3 are Associated with Overall and CV Mortality in HD and CKD ABI 0.9-1.3 ABI 0.9-1.3 ABI<0.9 ABI<0.9 ABI 1.3 ABI 1.3 Overall Survival Cardiovascular Survival N=69, Stage 3-5, HDN=231 Chen & Chen, Nephrology 2010;15:294-9

Either ABI<0.9 or 1.3 is Associated with LVH in CKD 28 N=684, Stage 3-5 Su & Chen, PLoS One 2012;7(9):e44732

29 High bapwv is Associated with Rapid Renal Function Decline and Progression to Dialysis and Death in CKD bapwv below Median bapwv above Median egfr Slope Combined end point-free Survival bapwv: brachial artery Pulse Wave Velocity (Arterial stiffness) N=145, Stage 3-5, Follow 14m Chen & Chen, CJASN 2011;6:724-32

High bapwv and High bpep/bet are Associated with Rapid Renal Function Decline and Progression to Dialysis in CKD L bapwv L bapwv H bapwv H bapwv L bpep/bet H bpep/bet L bpep/bet H bpep/bet N=243, Stage 3-5 Chen & Chen, Hypertens Res 2012;35:1159-63 30

31 Four-Limb BP High BP is an established modifiable risk factor for cardiovascular disease and mortality. However, the association between BP and cardiovascular risk weakens in the elderly. J Hypertens 24:287-292, 2006 A major confounding factor is atherosclerotic PAD. When PAD is present in subclavian and brachial arteries, arm BP cannot be accurately measured, and HT therefore cannot be timely diagnosed and properly managed in clinical practice. Lane D et al, J Hypertens 20:1089-1095, 2002

32 Interarm BP Difference National Institute for Health and Clinical Excellence (NICE) clinical guideline for hypertension a difference of < 10 mmhg can be regarded as normal a difference of > 20 mmhg between arms is unusual occur in less than 4% of people usually associated with underlying vascular disease

33 Interarm BP Difference is associated with PAOD and LVH N=1120 Su & Chen, PLoS One 2012;7:e41173

Interleg BP Difference Predicts Overall and CV Mortality in HD 34 Normal Interleg BP D. Normal Interleg BP D. log-rank P<0.001 log-rank P<0.001 Interleg Diffe. of SBP 15mmHg or DBP 10mmHg Interleg Diffe. of SBP 15mmHg or DBP 10mmHg Overall Survival N=110, Follow up 4.4±1.5y Cardiovascular Survival Chen & Chen, CJASN 2012;7:1646-53

35 Interankle SBP Difference is Associated with a 25% Decline in egfr Interankle SBP D. 6mmHg log-rank p = 0.024 Interankle SBP D. 6mmHg N=1445, Stage 3-5, Follow 3.1y Chen & Chen, Nephrology 2016;21:379-86

Overhydration is Associated with Progression to RRT in CKD 36 N=472, Stage 4-5, Follow 17.3m Tsai & Chen, AJKD 2014;63:68-75

Overhydration is Associated with Overall and CV Mortality in CKD 37 Entire Cohort N=478 HS<7% N=239 HS 7% N=239 P-value Patient-year of follow-up 763.5 434.4 329.1 <0.001 Combined outcomes per 100 patient-year (95%CI) 8.6 (6.7-11.0) 4.4(26.4-68.4) 14.3(10.5-19.0) <0.001 Cardiovascular morbidity per 100 patient-year (95%CI) 6.7(5.0-8.8) 3.0(1.6-5.1) 11.5(8.2-15.9) <0.001 Death per 100 patient-year (95%CI) 3.3(2.1-4.8) 1.4(0.5-3.0) 5.8(3.5-9.0) 0.008 Data are expressed as number (percentage) for categorical variables and median (25 th, 75 th percentile) for continuous variables, as appropriate. Abbreviations: HS, relative hydration status P-value was measured by comparisons between participants with HS 7% and those with HS<7%. N=478, Stage 4-5, Follow 23.2m Tsai & Chen, CJASN 2015;10:39-46

38 Heart Rate Variability (HRV) Heart rate variability (HRV) is used to evaluate the cardiovascular autonomic neuropathy. HRV is defined as variations of both instantaneous heart rate and R-R intervals of ECG. HRV may provide a simple and noninvasive way in assessing the activities of the autonomic nervous system. HRV has been categorized into high-frequency (HF) and low-frequency (LF) ranges. Normalized LF(LF%) is considered to mirror the sympatho-vagal balance or to reflect sympathetic modulation.

39 Some HRV Parameters Increased in Patients without Peripheral Artery Disease (PAD) in HD HRV parameters (frequency domain) Without PAD With PAD Before HD After HD Before HD After HD LF (ms 2 ) 2.5 ± 0.4 2.9 ± 0.5 1.6 ± 0.6 2.7 ± 0.6 HF (ms 2 ) 2.3 ± 0.4 2.7 ± 0.4 * 1.6 ± 0.7 2.5 ± 0.7 LF% (nu) 42.2 ± 2.2 47.0 ± 2.0 * 35.3 ± 3. 40.4 ± 3.4 HF% (nu) 33.0 ± 1.6 30.3 ± 1.3 33.2 ± 1.9 30.2 ± 1.9 LF/HF 0.22± 0.12 0.46 ± 0.10 * -0.07 ± 0.17 0.16 ± 0.16 N=161 HD Chen & Chen, PLoS One 2015;10:e0120459

LF%(Normalized Low Frequency for HRV) Predicts Overall and CV Survival in HD 40 p = 0.006 p = 0.029 Overall Survival N=182 HD, Follow 35.2m Cardiovascular Survival Chen & Chen, Sci Rep 2016;6:20597

41 Cholesterol Iseki K et al, Kidney Int 2002; 61 :1887 93

Cholesterol is Associated with Renal Outcomes in CKD 42 Renal replacement therapy Rapid renal progression Unadjusted Adjusted Unadjusted Adjusted Total cholesterol HR (95% CI) HR (95% CI) OR (95% CI) OR (95% CI) Quintile 1 1.33 (1.10, 1.61)* 1.23 (1.01, 1.49)* 1.12 (0.86, 1.46) 1.06 (0.79, 1.42) Quintile 2 1 1 1 1 Quintile 3 0.90 (0.74, 1.10) 1.08 (0.88, 1.33) 1.05 (0.81, 1.38) 1.17 (0.87, 1.57) Quintile 4 1.15 (0.95, 1.39) 1.25 (1.02, 1.52)* 1.18 (0.90, 1.54) 1.20 (0.89, 1.61) Quintile 5 1.36 (1.13, 1.64)* 1.35 (1.11, 1.65)* 1.98 (1.53, 2.55)* 1.36 (1.01, 1.83)* *p < 0.05; **p < 0.001 compared to quintile 2 N=3,303, Stage 3-5, Follow 2.8y Chen & Chen, PLoS One 2013;8:e55643

Proteinuria Modify the Relationship Between Lipid Profile and Mortality in CKD 43 TC & TC/HDL-- Overall mortality if UPr<1g/D TC/HDL-- Overall mortality if UPr 1g/D N=3,303, Stage 3-5, Follow 2.8y Chen & Chen, CJASN 2013 ;8:1915-26

4 4 Summary Cardiovascular diseases are common in CKD, and CKD has been recognized as a major risk factor for CVD. Many nontraditional risk factors also contribute to CVD and should not be missed. We should recognize patients at risk and provide early prevention and treatment.

Thank you for your attention